Clene Inc. (CLNN): Price and Financial Metrics

Clene Inc. (CLNN): $0.40

0.01 (+1.30%)

POWR Rating

Component Grades








Add CLNN to Watchlist
Sign Up

Industry: Biotech




#353 of 367

in industry

CLNN Price/Volume Stats

Current price $0.40 52-week high $0.97
Prev. close $0.39 52-week low $0.25
Day low $0.37 Volume 1,399,000
Day high $0.41 Avg. volume 863,384
50-day MA $0.37 Dividend yield N/A
200-day MA $0.43 Market Cap 50.90M

CLNN Stock Price Chart Interactive Chart >

Clene Inc. (CLNN) Company Bio

Clene Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of unique therapeutics for neurodegenerative diseases. Clene provides nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs.

CLNN Latest News Stream

Event/Time News Detail
Loading, please wait...

CLNN Latest Social Stream

Loading social stream, please wait...

View Full CLNN Social Stream

Latest CLNN News From Around the Web

Below are the latest news stories about CLENE INC that investors may wish to consider to help them evaluate CLNN as an investment opportunity.

Clene Announces New Data from HEALEY ALS Platform Trial

LOS ANGELES, CA - (NewMediaWire) - December 22, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN) (along with its subsidiaries, "Cl...

Yahoo | December 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | December 21, 2023

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18 months, p=0.0167) in participants originally randomized to CNM-Au8 30mg compared to those originally randomized to placebo using the rank-preserving structural failure time model (RPSFTM) CNM-Au8 30mg had greater overall treatment effect in delaying the time to morbid

Yahoo | December 21, 2023

Clene Provides Update on ALS Clinical Development Meeting With FDA

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Admini

Yahoo | December 21, 2023

How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

LOS ANGELES, CA - (NewMediaWire) - December 19, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene, a late clinical-stage biopharmaceutical company...

Yahoo | December 19, 2023

Read More 'CLNN' Stories Here

CLNN Price Returns

1-mo 14.84%
3-mo -9.91%
6-mo N/A
1-year -50.00%
3-year -96.32%
5-year N/A
YTD 34.86%
2023 -70.34%
2022 -75.61%
2021 -54.50%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!